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Immunity to infections with measles virus (MV) can involve vigorous human leukocyte 
antigen (HLA) class I-restricted CD8+ cytotoxic T cell (CTL) responses. MV, albeit 
regarded monotypic, is known to undergo molecular evolution across its RNA genome. 
To address which regions of the MV proteome are eligible for recognition by CD8+ CTLs 
and how different HLA class I loci contribute to the epitope display, we interrogated the 
naturally processed and presented MV peptidome extracted from cell lines expressing 
in total a broad panel of 16 different common HLA-A, -B, and -C molecules. The reper-
toire and abundance of MV peptides were bona fide identified by nanoHPLC–MS/MS. 
 Eighty-nine MV peptides were discovered and assignment to an HLA-A, -B, or -C allele, 
based on HLA-peptide affinity prediction, was in most cases successful. Length variation 
and presentation by multiple HLA class I molecules was common in the MV peptidome. 
More than twice as many unique MV epitopes were found to be restricted by HLA-B 
than by HLA-A, while MV peptides with supra-abundant expression rates (>5,000 cc) 
were rather associated with HLA-A and HLA-C. In total, 59 regions across the whole MV 
proteome were identified as targeted by HLA class I. Sequence coverage by epitopes 
was highest for internal proteins transcribed from the MV-P/V/C and -M genes and 
for hemagglutinin. At the genome level, the majority of the HLA class I-selected MV 
epitopes represented codons having a higher non-synonymous mutation rate than 
silent mutation rate, as established by comparison of a set of 58 unique full length MV 
genomes. Interestingly, more molecular variation was seen for the epitopes expressed at 
rates ≥1,000 cc. These data for the first time indicate that HLA class I broadly samples 
the MV proteome and that CTL pressure may contribute to the genomic evolution of MV.
Keywords: hla class i, measles virus, cD8 T cell epitope, immunodominance, epitope mapping, hla-a antigens, 
hla-B antigens, hla-c antigens
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inTrODUcTiOn
Measles is a highly contagious disease, caused by the measles 
virus (MV), an enveloped single-stranded Morbillivirus. MV 
has no animal reservoir and can only be maintained in human 
populations by a continuous chain of acute infections. A single 
attack of measles as well as receiving two doses of an attenu-
ated MV vaccine confer life-long immune protection (1). This 
is remarkably different from many other viruses that can cause 
(re-)infections within several years by readily adapting to the 
host immune response. MV is regarded serologically monotypic 
although genomic variation is observed across the RNA genome. 
Based on comparison of genes encoding envelope proteins that 
are suspected to encounter immune pressure from neutralizing 
antibodies, MV molecular evolution is considered modest rela-
tive to other viruses (2, 3). This may suggest that specific immune 
responses to MV are relatively modest, yet, on the contrary, MV 
evokes considerable immune responsiveness, underlying the 
host’s long-lived protection (4, 5). At the same time, and this 
is often regarded as the “measles paradox,” the acute phase of 
measles is also associated with strong immune suppression for 
up to months, which causes significant secondary morbidity 
and mortality (6, 7). Viral mechanisms have been proposed to 
account for this, including MV infection of dendritic cells (6, 
8, 9), and more recently, infection of CD150 positive memory 
T cells and follicular B cells (10). Previously, we have pointed out a 
possible molecular mechanism connecting vigorous MV-specific 
immunity to the observed immune suppression (4). A single viral 
peptide was found to dominate the peptide repertoire presented 
at the surface of a MV-infected human B lymphoblastoid cell line 
(BLCL) in the context of the human leukocyte antigen (HLA) 
class I molecule HLA-A2 (11). This supra-abundant peptide, 
spanning amino acids (aa) 84–92 from the non-structural C 
protein (MV-C84–92), induced vigorous CD8+ T cell expansions in 
acute measles patients to estimated peak fractions of 7.5–15% of 
specific CD8+ T cells (4). We postulated that such an epitope could 
account for CD8+ T cell-mediated mass destruction of infected 
immune cells in hosts with this particular HLA type. Notably, the 
apparent genetic variation in this epitope, abrogating its binding 
to the HLA-A2 molecule (11), indirectly suggested that effective 
anti-viral immunity is at play that may induce immune escape. 
Yet to account for the general immune suppression observed after 
measles, this phenomenon cannot be limited to a single epitope in 
HLA-A2 but should rather involve other HLA class I molecules 
as well. In principle, every HLA class I molecule on nucleated 
cells binds small peptides, generated by proteolysis from cyto-
solic proteins, and presents it as an HLA class I-peptide complex 
(HLAp) at the cell surface to CD8+ T cells. Which peptides are 
picked up by HLA-A, -B, and -C molecules in the class I loading 
pathway depends on their unique peptide binding motifs. These 
motifs and the available “degradome” determine the expression 
of a particular HLAp, which can range from 1 to 10, 100 to 1,000, 
or even from 10 to 100,000 copies per cell (cc) (11, 12). Recently, 
using advanced mass spectrometry technology, we found that 
repertoires of self peptides presented by a set of HLA-A alleles 
were less diverse than those presented by their co-expressed 
HLA-B alleles, allowing potentially more dominance by HLA-A 
peptide cargo (13). Here, we tested the hypothesis that HLA-A 
alleles favor the presentation of supra-abundant MV peptide spe-
cies. We analyzed MV-specific HLAp repertoires presented 48 h 
after MV infection in the context of in total 16 different HLA-A, 
-B, and -C molecules.
MaTerials anD MeThODs
cell lines and MV infection
Four human BLCL, 1053, 1077, 1090, and 1112 (kindly provided 
by Dr. T. Mutis, VUmc, The Netherlands) were grown in RPMI-
1640 medium supplemented with penicillin, streptomycin, and 
10% heat-inactivated fetal calf serum (FCS). Together the BLCL 
express five different HLA-A, six different HLA-B, and five dif-
ferent HLA-C alleles (Table 1), covering >70 and >50% of the 
HLA-A- and HLA-B allele usage in the Caucasian population, 
respectively. Approximately 2  ×  108 cells of each BLCL were 
infected at an m.o.i of 0.5 for 48 h in RPMI-1640 medium sup-
plemented with antibiotics and 2% FCS using plaque-purified 
MV (Edmonston B strain), propagated on Vero cells. This 
procedure yields >90% infected cells, based on expression of 
MV-Hemagglutinin (MV-H). Approximately 2  ×  108 cells of 
each BLCL were left uninfected. Infected and uninfected (con-
trol) BLCL batches were harvested, washed three times in cold 
PBS, pelleted, snap-frozen, and stored at −70°C until further 
use. Pre- and post-infection cell viability was high. MV infection 
did not affect the expression of total HLA class I molecules, of 
HLA-A*02 molecules nor of HLA-B and -C molecules as was 
assessed by flowcytometric analysis of HLA-typed BLCL using 
the monoclonal antibodies W6/32, BB7.2 (if applicable) and 
B1.23.2, respectively.
isolation of hla class i-Bound Peptides
HLA class I-peptide complex were isolated from uninfected and 
48 h MV-infected BLCL using W6/32 as described previously (11). 
Briefly, cells were solubilized in lysis buffer containing CHAPS 
and protease inhibitors. After centrifugation at 10,000 × g for 1 h 
at 4°C, supernatants were precleared with CNBr-activated and 
Tris-blocked control sepharose beads and beads coupled to nor-
mal mouse serum, respectively, and cleared with beads coupled 
to W6/32. Immunoprecipitated HLAp were eluted from the beads 
with 10% acetic acid and peptides were collected by passage over 
a 10-kDa MW cut-off membrane filter. The eight filtrated eluates 
were concentrated by vacuum centrifugation.
nanoscale liquid chromatography-Mass 
spectrometry and epitope identification 
and semiquantification
Each eluate was reconstituted in 0.1% (v/v) TFA and fraction-
ated into 26 fractions using strong cation exchange (SCX) 
chromatography on a 200-μm I.D. PolySULFOETHYL Aspartide 
column (packed in-house), running a linear KCl-gradient start-
ing with water in 0.5% (v/v) acetic acid to 500  mM and 35% 
(v/v) acetonitrile in 0.5% (v/v) acetic acid. Fractions were dried 
by vacuum centrifugation and reconstituted in water containing 
5% formic acid and 5% dimethylsulfoxide. Peptide analyses on 
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fractions using equivalents of ~50 × 106 cells were performed on 
a nanoscale LC-MS system, essentially as described by Meiring 
et al. (14), comprising a 50- and 25-μm I.D. Reprosil-Pur C18-AQ 
trapping and analytical column, respectively (packed in-house). 
High-resolution MS1 data were acquired on an LTQ-Orbitrap 
XL mass spectrometer (Thermo Scientific, San Jose, CA, USA) 
at a resolution of 60,000 FWHM and CID MS/MS fragmentation 
spectra were acquired on-the-fly in the LTQ mass analyzer on 
the doubly and triply charged ions only. Peptide identification 
(with a false discovery rate of 5%) was performed with BioWorks 
3.3.1 SP1 (Thermo Scientific, San Jose, CA, USA) against the 
human-annotated and MV-annotated proteins extracted from 
the UniProtKB/Swiss-Prot database (Swiss-Prot database version 
57.10 with taxonomy identifier “Homo Sapiens” and “Measles 
Virus”, respectively)1. No enzyme cleavage specificity was used 
as a filter during the database search. Moreover, deamidation of 
N, oxidation of M, and phosphorylation of S, T, and/or Y were 
considered as dynamic modifications during the peptide identi-
fication process. Candidate peptides that were discovered in this 
process as MV-derived peptides were validated manually based on 
their MSMS spectrum and by confirmation of absence from the 
corresponding control eluate by comparative ion mapping. For 
semiquantification of peptide expression levels, known amounts 
of two internal standard peptides, Angiotensin-III and Oxytocin 
(Sigma-Aldrich, St Louis, MO, USA) were added to each of the 
SCX fractions and their response factors in the MS analysis (total 
counts under the peak curve/mole) were determined. Expression 
levels for the MV-derived peptides were calculated and given as 
copies per cell (cc), based on their counts in an SCX fraction (area 
under the curve) and based on the assumption of equal response 
factors for MV-derived peptides and the internal standard pep-
tides. Experiments were performed as unique experiments due to 
their laborious nature.
1 www.uniprot.org
TaBle 1 | summary of hla class i alleles and number of identified MV peptides and source proteins per Blcl.
cell line hla-a hla-B hla-c MV peptides MV proteins represented
BLCL1053 A*02:01 B*07:02 C*07:02 27a (13, 7, 2, 5)b 7
A*03:01 B*07:02 C*07:02
BLCL1077 A*01:01 B*08:01 C*03:04 12 (0, 12, 0, 0) 5
A*24:02 B*40:01 C*07:01
BLCL1090 A*02:01 B*35:01 C*04:01 22 (10, 10, 0, 2) 7
A*11:01 B*44:02 C*05:01
BLCL1112 A*02:01 B*15:01 C*03:04 28 (7, 11, 1, 9) 7
A*02:01 B*44:02 C*05:01
Total 89c,d (30, 40, 3, 16) 8
Total unique 5 6 5 70e (18, 38, 3, 11)
aNumber of unique HLApMV combinations identified per cell line.
bBetween brackets the number of assignments to HLA-A, -B, -C, and NA, respectively.
cTotal number of HLApMV combinations identified in this study.
dA cumulative list of all identified HLApMV combinations with detailed information on source sample, allele assignment, and expression rate is given in Table S2 in Supplementary 
Material.
eUnique HLApMV combinations are short-listed in Table 2.
Peptide assignment to hla class i alleles
W6/32-isolated HLAp contain all groups of HLA class I mol-
ecules (HLA-A, -B, and -C). HLA molecules expressed per 
BLCL had little overlap in binding motifs, minimizing the level 
of cross-presentation (i.e., the presentation of the same peptide 
by two or more distinct HLA alleles). For each of the eluted 
MV peptides, an HLA class I allele was predicted using the 
NetMHC-3.2 algorithm (15, 16) for the respective BLCL’s HLA-A 
and -B alleles, and NetMHCpan-2.4 (17, 18) for HLA-C alleles, 
giving a binding prediction based on affinity scores. Because 
affinity scores for different HLA alleles may not necessarily be 
comparable, each peptide was also ranked among a set of 100,000 
random natural peptides. A peptide was assigned to an HLA 
isotype (among all HLA isotypes expressed by a given BLCL) for 
which the peptide showed the highest ranking, while having a 
predicted affinity score <5,000 nM IC50. In addition, the ranking 
had to be among the top 5% for HLA-A and -B alleles and the 
top 10% for HLA-C alleles. We repeated the peptide assignment 
procedure also based on predicted binding affinity. A peptide 
was assigned to an HLA-C molecule only if the peptide did not 
rank among the top 5% for any of the respective BLCL’s HLA-A 
or -B isotypes, because prediction tools for the HLA-C locus do 
not reach the same prediction performance as for HLA-A and 
-B alleles. Peptides that failed to exceed the prediction score or 
ranking cut-off for any of the HLA-A, -B, and -C alleles remained 
“non-assigned” (NA). The assignment approach was validated by 
consolidating self peptide repertoires assigned to HLA-B*40:01 
and -B*4402 by Hillen et al. (19) in our self peptide dataset (13).
MV sequence alignment and Variability 
analysis
Nucleotide gene sequences for nucleoprotein (MV-N), phos-
poprotein (MV-P), V protein (MV-V), C protein (MV-C), 
matrix protein (MV-M), fusion protein (MV-F), hemagglutinin 
(MV-H), and polymerase (MV-L) from 58 unique full-length 
sequenced MV genomes were obtained from Genbank (Table S1 
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in Supplementary Material), aligned, and translated using 
BioEdit (version 7.2.4) software. SNAP v2.1.1 software2 was 
used for codon analysis and calculation of non-synonymous and 
synonymous substitution rates, dN and dS, respectively.
statistical analysis
For data analysis and visualization of data GraphPad Prism 
(Version 6.05) was used. To test associations between the propor-
tion of codons with dN > dS of total epitope codons with either 
HLA class I locus (HLA-A versus HLA-B) or with epitope abun-
dance (<1,000 versus ≥1,000 cc), the Fisher’s exact contingency 
test was used (Table S4 in Supplementary Material). P–values 
<0.05 were considered statistically significant.
resUlTs
high-resolution MV Peptide identification 
by Mass spectrometry
Peptide repertoires were eluted from HLA class I molecules 
expressed on MV-infected BLCL1053, -1077, -1090, and -1112, 
fractionated, analyzed by high-resolution nano-LC-MS and 
mass sequencing, and searched for the presence human and 
MV sequences. As expected, each eluate contained thousands 
of distinct peptides, mostly self peptides (13). Each eluate also 
contained multiple peptides unique for MV, based on peptide 
fragmentation and comparative ion mapping in control samples. 
As an example, ion 537.295  Da (MH2+), present in the eluate 
of MV infected but not of uninfected BLCL1112 (Figure S1 in 
Supplementary Material, lower versus upper panel, respectively), 
was identified by mass sequencing as KIIDNTEQL. This peptide 
represented aa 204–212 from the MV-M (M.204.09) (Figure 
S1 in Supplementary Material). Collectively in the four post-
infection eluates, 89 MV-specific peptide identifications were 
made (Table 1).
assignment of hla class i alleles and 
expression rate of the identified MV 
Peptidome
Based on HLAp affinity prediction (see Materials and Methods) 
KIIDNTEQL peptide described above was assigned as a ligand 
of HLA-A*02:01, one of the expressed HLA class I molecules of 
BLCL1112. In addition, the expression rate of M.204.09, i.e., the 
number of HLA-A*02:01 molecules on BLCL1112 cells loaded 
with KIIDNTEQL, was semi quantitated using internal standard 
peptides (see Materials and Methods) (4,666  cc). Similarly, all 
89 MV peptides identified in this study were allocated to their 
best predicted HLA class I molecule and semi quantitated. Thirty 
eluted MV peptide sequences were allocated to HLA-A alleles, 
40 to HLA-B alleles, 3 to an HLA-C allele, and 16 could not be 
conclusively assigned to any single HLA molecule expressed 
by our BLCL (NA) (Table  1, details are given in Table S2 in 
Supplementary Material). Due to a partial overlap in HLA class I 
isotypes between BLCLs in this study, the same HLA-class I-MV 
2 http://www.hiv.lanl.gov/
peptide (HLApMV) combination could be found in peptide 
repertoires from two or three BLCL, as was observed for eight 
and four MV peptides, respectively. In three cases, a MV peptide 
had a length variant, discovered in the same eluate and assigned 
to the same allele. Such length analogs can be considered as 
representing the same MV epitope. After these considerations, 
70 unique HLApMV combinations were identified in this study, 
54% (n = 38) being assigned to HLA-B alleles, 26% (n = 18) to 
HLA-A alleles, 4% (n = 3) to HLA-C, and 16% (n = 11) remaining 
NA, respectively (Table  1). The HLApMV short-list represents 
mostly novel human HLA class I presented MV epitopes, with 
the exception of only four epitopes reported as CD8+ T cell targets 
earlier (Table 2) (4, 11, 20–24).
MV Peptide length Distribution and 
Dynamic range
To further characterize the MV peptide species involved, we ana-
lyzed their general length and global expression rate. Uniquely 
presented MV epitopes ranged in length from 8 to 16 aa, with 
nonamers being most common (46%), followed by deca- (14%), 
octa-, and undecamers (both 2.9%) (Figure 1A). Based on peptide 
quantity, i.e., counting all copy numbers of HLApMV complexes 
of a given peptide length and summing these for all BLCL, nonam-
ers are composed 81% of the total MV peptide repertoire studied, 
with percentages for octa-, deca-, undeca-, and dodecamers of 
4, 1, 10, and 4%, respectively (data not shown). As depicted in 
Figure 1B, nonamers were dominant in the HLA-A and HLA-B 
sets of MV peptides, with other lengths occurring as well, includ-
ing octamers and non-canonically long peptides (>11 aa). All 
three HLA-C-assigned peptides were nonamers. Furthermore, 
individual HLApMV combinations differed remarkably in their 
expression rate on BLCL, illustrating a dynamic range from as 
few as 1–10 to >35,000 cc (Figure 2A), while median expression 
rates were comparable between the four BLCL, i.e., 129, 99, 87, 
and 167 cc, respectively.
hla class i allele Usage and hierarchy of 
individual MV Peptides
To study the role of the different HLA class I gene loci and alleles 
in MV peptide presentation in more detail, we analyzed the diver-
sity and abundance of the MV peptides assigned per HLA class 
I molecule per individual BLCL. As is shown in Figure 3A, for 
each BLCL multiple MV peptides were identified yet these were 
not equally distributed over HLA class I molecules expressed. 
MV peptides were assigned to all six HLA-B alleles in the study, 
i.e., B*07:02 (n = 6 peptides), B*08:01 (n = 7), B*15:01 (n = 8), 
B*35:01 (n = 8), B*40:01 (n = 5), and B*44:02 (n = 3). For the 
other loci and their alleles, MV peptides were only allocated to 
HLA*A*02:01 (n = 11), A*03:01 (n = 5), A*11:01 (n = 2), C*03:04 
(n = 1), and C*07:02 (n = 2). The 11 NA MV peptide species, 
three of which were confirmed on two different BLCL, and one on 
three different BLCL, respectively, were relatively low-abundant 
(geomean of 39 cc, Figure 2B). HLA-A and HLA-B-assigned MV 
peptides generally had a higher expression rate (geomean of 160 
and 148 cc, respectively). Of interest, HLA-A-associated MV pep-
tides reached highest absolute numbers than HLA-B-associated 
TaBle 2 | cumulative list of unique eluted hlapMV combinations.
Unique hlapMV MV epitope sequence MV epitope codea Best hla class i allele reference
1 YPALGLHEF N.281.09 HLA-B*07:02 This study
2 YPALGLHEF N.281.09 HLA-B*35:01 This study
3 GPRQAQVSF(L) N.411.09 (10) HLA-B*07:02 This study
4 DALLRLQAM N.493.09 HLA-B*08:01 This study
5 TDTPIVYNDRNL(LD) N.512.12 (14) NA This study
6 EPIGSLAIEEAM P.022.12 HLA-B*35:01 This study
7 YVYDHSGEAVK P.111.11 HLA-A*03:01 This study
8 YVYDHSGEAVK P.111.11 HLA-A*11:01 This study
9 GSAPISMGFR P.169.10 HLA-A*03:01 This study
10 AEGGEIHEL P.185.09 HLA-B*40:01 This study
11 FPKLGKTL P.203.08 HLA-B*08:01 This study
12 KKQINRQN P.350.08 NA This study
13 DTGVDTRIW V.282.09 NA This study
14 AVRDLERAM C.072.09 HLA-C*03:04 This study
15 AVRDLERAMTTLK C.072.13 HLA-A*03:01 This study
16 KLWESPQEI C.084.09 HLA-A*02:01 This study (4, 11, 21–24)
17 QEISRHQALGY C.090.11 HLA-B*44:02 This study
18 GRLVPQVRVID M.029.11 NA This study
19 LLKEATEL M.090.08 HLA-B*08:01 This study
20 GLNEKLVFY M.106.09 HLA-B*15:01 This study
21 RLSDNGYYTV M.164.10 HLA-A*02:01 This study (22)
22 FRSVNAVAF M.180.09 HLA-C*07:02 This study
23 GKIIDNTEQL M.203.10 NA This study
24 KIIDNTEQL M.204.09 HLA-A*02:01 This study
25 VIINDDQGLFKV M.323.12 HLA-A*02:01 This study
26 DQGLFKVL M.328.08 NA This study
27 EPIRDALNAM F.085.10 HLA-B*35:01 This study
28 SMLNSQAIDNLRA F.140.13 HLA-A*02:01 This study
29 RQAGQEMILAV F.165.11 HLA-A*02:01 This study
30 RQAGQEMILAV F.165.11 HLA-B*15:01 This study
31 RITHVDTESY F.268.10 HLA-B*15:01 This study
32 GPPISLERLDVGTN F.449.14 NA This study
33 RPGLKPDL F.532.08 HLA-B*07:02 This study
34 LMIDRPYVL H.030.09 HLA-A*02:01 This study (4, 11, 21, 23, 24)
35 AIYTAEIHK H.064.09 HLA-A*03:01 This study
36 AIYTAEIHK H.064.09 HLA-A*11:01 This study
37 LETRTTNQFL H.172.10 HLA-B*40:01 This study
38 PTTIRGQFS H.191.09 NA This study
39 GMYGGTYLVEK H.226.11 HLA-A*03:01 This study
40 KPNLSSKRSEL H.236.11 HLA-B*07:02 This study
41 SMYRVFEV H.250.08 HLA-A*02:01 This study (22)
42 APVFHMTNY H.267.09 HLA-B*35:01 This study
43 APVFHMTNYLEQPVS(N) H.267.15 (16) NA This study
44 IPYQGSGKGVSF H.308.12 HLA-B*07:02 This study
45 IPYQGSGKGVSF H.308.12 HLA-B*35:01 This study
46 IPPMKNLAL H.456.09 HLA-B*08:01 This study
47 KVSPYLFTV H.477.09 HLA-A*02:01 This study
48 AEVDGDVKL H.502.09 HLA-B*40:01 This study
49 ARVPHAYSL L.0032.09 HLA-C*07:02 This study
50 LLKKGNSLY L.0109.09 HLA-B*15:01 This study
51 DIKEKVINL L.0144.09 HLA-B*08:01 This study
52 ISKESQHVY L.0213.09 HLA-B*15:01 This study
53 KESQHVYYL L.0215.09 HLA-B*40:01 This study
54 KLIDGFFPA L.0263.09 HLA-A*02:01 This study
55 YLKDKALA L.0463.08 HLA-B*08:01 This study
56 KEIKETGRLF L.0537.10 HLA-B*44:02 This study
57 AENLISNGIGKY L.0560.12 HLA-B*44:02 This study
(Continued)
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FigUre 2 | comparison of abundances of the 89 individually identified 
hlapMV combinations. (a): abundance of uniquely identified HLApMV 
combinations per BLCL. (B): abundance of uniquely identified HLApMV 
combinations plotted per assigned HLA class I category. Each symbol 
represents an individual HLApMV combination from the summed 89 MV 
peptides identified in the four BLCL eluates (hence length variants shown 
individually). Numbers between brackets are total number of HLApMV 
complexes per BLCL (a) or total number of HLApMV complexes  
per locus (B).
Unique hlapMV MV epitope sequence MV epitope codea Best hla class i allele reference
58 AQRLNEIY L.0680.08 HLA-B*15:01 This study
59 YESGVRIASL L.0760.10 HLA-B*40:01 This study
60 IVSSHFFVY L.0824.09 HLA-B*15:01 This study
61 LPAPIGGMNY L.0933.10 HLA-B*35:01 This study
62 SLMPEETLHQV L.0971.11 HLA-A*02:01 This study
63 MPEETLHQVM L.0973.10 HLA-B*35:01 This study
64 RPIYGLEV L.1152.08 HLA-B*07:02 This study
65 SAVRIATVY L.1237.09 HLA-B*35:01 This study
66 (K)KVDTNFIY(QQ) L.1325.09 (L.1326.10) NA This study
67 HILAKSTAL L.1434.09 HLA-B*08:01 This study
68 SMIDLVTKF L.1443.09 HLA-B*15:01 This study
69 HYREVNLVY L.1936.09 NA This study
70 SQQGMFHAY L.2076.09 HLA-B*15:01 This study
aCode “x.(y)yyy.zz” of a measles virus peptide (pMV), in which x encodes the source protein (N, nucleocapsid; P, phosphoprotein; V, V protein; C, C protein; M, matrix protein;  
F, fusion protein; H, hemagglutinin; L, polymerase), (y)yyy encodes the position of the first aa in the protein, and zz represents the length of a peptide, respectively.  
Boxed epitopes represent identical or overlapping but differentially assigned epitope sequences.
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MV peptides, with 36,108 cc observed for the most abundant and 
dominating peptide in HLA-A*02:01 (C.084.09 in BLCL1112) 
versus 4,219 cc for the most abundant peptide in HLA-B*07:02 
(N.411.10 in BLCL1053), respectively. High abundance was also 
seen in HLA-C: one (of three) identified peptides, M.180.09, 
was found at 8,266  cc in HLA-C*07:02 (BLCL1053). Notably, 
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FigUre 1 | general characteristics of hla class i-eluted MV peptides. 
(a) Distribution of peptide lengths for 70 unique HLApMV combinations 
eluted from the four BLCL. (B) Relative distribution of peptide lengths plotted 
per HLA locus for all unique HLApMV combinations eluted from the four 
BLCL Peptides ≥14 aa are grouped. Numbers represent total MV peptides 
per assigned group. NA, not assigned.
BLCL1077 had a relatively low yield of MV peptides, both in 
number (Figure  3A) and abundance (Figure  3B), and only 
yielded HLA-B-associated MV peptides (though not being 
homozygous for HLA-B).
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per BLCL (B).
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MV Proteome coverage and strain 
Variability of hla class i-selected epitope 
regions
We next examined the viral proteome represented by the 70 
identified HLApMV combinations. In 11 cases, (near) identical 
or overlapping MV peptide sequences were assigned differently 
in different cell lines, e.g., to two separate HLA class I molecules 
(n =  8) or to one HLA class I allele and the other remaining 
NA (n = 3), Table S2 in Supplementary Material). Taking these 
into account, the HLApMV panel involved 59 different source 
regions, which were scattered throughout the MV proteome, 
implying all eight MV proteins (Figure  4). MV-P and MV-V 
are expressed from the same P gene segment by a process called 
RNA editing (25) and share their N terminal part (aa 1–231). 
As indicated, this shared N terminal domain yielded five MV 
peptides, hence both proteolysis of MV-P and of MV-V could 
account for these. The unique C-termini of MV-P and MV-V also 
generated one additional HLApMV species each (Figure 4). Of 
the total expressed MV proteome (5,202 aa), the identified HLA 
class I-presented MV ligandome comprised 12.2% (n = 635 aa). 
The relative sequence coverage was highest for MV-M (7 epitopes, 
representing 70 aa of 335 aa, 20.9%) and lowest for MV-N 
(4 epitopes, representing 42 aa of 525 aa, 8.0%) (Figure 5).
Since molecular evolution of MV genomes has been con-
sidered slow but nevertheless subject to selective pressure of 
immune responses (2), we performed a preliminary analysis of 
the occurrence of non-synonymous substitution rates (dN) in 
codons from all MV epitope regions relative to the occurrence 
of synonymous substitution rates (dS) and the overall genomic 
evolution in their source proteins using a database of 58 full-
length publicly available unique MV genomes (listed in Table 
S1 in Supplementary Material) and SNAP v2.1.1 software (see 
Materials and Methods). Eleven of the 59 epitope regions did 
not contain any codons with non-synonymous substitutions, the 
other 48 regions containing at least one codon with a non-synon-
ymous substitution (median 2, range 1–7) (Raw data showing the 
variability analysis of the full-length proteins are given in Table 
S3 in Supplementary Material, a summary of the microvariation 
in MV epitopes is given in Table S4 in Supplementary Material). 
Epitopes lacking non-synonymous substitutions (dN = 0) were 
mostly from MV-L (9/11), with one other epitope from MV-N 
and one from MV-F (Table S4 in Supplementary Material). In 
88 of 132 codons representing epitope regions displaying aa 
variation, dN was greater than dS (dN >  dS). When omitting 
epitope regions of the genomically conserved MV-L from this 
list, we noted a trend that HLA-A associated epitope regions had 
a higher proportion of codons with dN > dS of their total number 
of codons than HLA-B-associated epitope regions (22.2 versus 
14.1%, p = 0.0795). Moreover, for epitopes with abundances of 
≥1,000 cc, the proportion of dN > dS-codons was significantly 
higher than epitope regions with abundances <1,000  cc (28.9 
versus 15.2%, p = 0.0061) (Table S4 in Supplementary Material).
Codons with dN >  dS were observed throughout the MV 
proteome, in some protein sequences more frequently than in 
others and not limited to the epitope regions identified in this 
study (Table S3 in Supplementary Material). Our list of epitope 
regions likely underrepresents the full MV immunopeptidome, 
due to sensitivity limits of MHC peptide elution methods and the 
selective panel of HLA class I alleles investigated. A preliminary 
comparison of the proportion of codons with dN > dS in regions 
representing epitopes elucidated in this study (including MV-L 
epitopes) versus regions not representing epitopes indicated an 
increased occurrence of codons with higher dN than dS in the 
current epitope list (data not shown).
DiscUssiOn
Cutting edge mass spectrometric analysis has allowed us to extend 
our knowledge on the selection and presentation of MV-derived 
peptides in the context of a broad set of HLA class I alleles. 
Seventy unique HLA class I peptide combinations representing 
59 viral epitope regions were identified as candidate targets for 
the CD8+ T cell response, mostly unknown to date (4, 11, 21–24). 
This is an unprecedented large set of naturally presented HLAp 
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revealed for a single virus. This comprehensive MV epitope land-
scape allowed us to make two major observations. The first, in 
line with our hypothesis, is that the most abundant peptide spe-
cies in our study were presented by HLA-A alleles, while HLA-B 
alleles displayed an overall more diverse set of MV peptides. The 
HLA-A*02:01-assigned MV-C.084.09 peptide was found in all 
three HLA-A*02:01 expressing MV-infected BLCL and appeared 
at high density, up to 36,000  cc, in accordance with earlier 
observations (11). The second most abundant HLA-A-associated 
epitope was MV-P.111.11, expressed by HLA-A*03:01 (5,279 cc). 
Remarkably however, and not corroborating with an HLA-A 
exclusive claim on supra-abundance, the HLA-C*07:02-assigned 
epitope M180.09 was also found at a high copy rate (>8,000 cc), 
for the first time implying the HLA-C locus in the presentation 
of epitopes at such remarkably high level of expression. This 
seems even more interesting in view of the substantially lower 
expression rate measured for HLA-C molecules compared to 
HLA-A and -B molecules on BLCL or PBMC, being up to 12- to 
13-fold lower depending on steady state or infection conditions 
(26). Although we have not assessed locus-specific expression 
of HLA class I molecules in a quantitative manner in our study, 
we could not observe overall changes in HLA class I expression 
upon MV infection of BLCL (see Materials and Methods).
No other HLA-A nor B or C alleles in our study were implied 
in supra-abundant expression rates >5,000 cc, yet HLA-B*08:01, 
HLA-B*15:01, and HLA-B*35:01 were found among the HLA 
class I alleles expressing several MV epitopes in the abundance 
range of 1,000–5,000  cc (Table S2 in Supplementary Material). 
Although still in a selection of HLA class I molecules, these 
observations might indicate that alleles from all three HLA-A, -B, 
and -C loci can, in principle, contribute to abundant viral epitope 
expression (≤5,000 cc) at the cell surface, but with certain HLA-A, 
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and -C alleles potentially driving supra-abundance for particular 
epitopes. Although we have not studied the new set of epitopes for 
T cell immunogenicity yet, based on earlier work it can be envis-
aged that supra-abundant epitopes may lead to dominant early 
expansion of CD8+ T cells which however decline below detection 
limit in the memory phase, as was found for the HLA-A*02:01 
binding MV-C.084.09 peptide (4). Other HLA class I alleles that 
presented peptides at a supra-abundant rate (>5,000  cc) were 
HLA-A*03:01 and HLA-C*07:02, which like HLA-A*02:01 are 
globally highly prevalent alleles3, implying that supra-abundance 
of MV epitopes is possible across populations. This feature 
could contribute to measles-associated immunosuppression by 
strong expansions in the specific CD8+ T cell compartment in 
large patient groups (5), wiping out not only large fractions of 
primary infected lymphocytes but also any target cell licensed to 
be killed by presenting peptide shed from infected cells. On the 
other hand, the more moderately expressed epitopes in the MV 
peptides landscape may underlie memory CD8+ T cell responses 
that do mediate effective long-lived CD8+ T cell memory. HLA-B 
molecules, being the most polymorphic of the HLA isotypes, may 
in particular contribute to this repertoire by accommodating a 
more diverse set of epitopes, as was shown for self-derived pep-
tides (13) as well as for MV peptides (this study). Whether this 
leads to more immunodominant MV-specific HLA-B-restricted 
CD8+ T cell responses in the memory phase, as has been seen in 
various other infectious models (27–30), remains to be elucidated 
in T cell studies using blood samples taken longitudinally after 
MV infection or immunization.
Hence, the extreme high and low abundance ends found in 
the MV epitope landscape observed could well contribute to the 
measles paradox of respective immunosuppressive and immunity 
mechanisms, generated in parallel. Notably, high copy number 
presentation by HLA-A*02:01 was recently suggested to play a 
3 www.allelefrequencies.net
role in the low-avidity non-protective cytotoxic T cell responses 
against the M158–66 Influenza peptide GILGFVFTL (31). Such 
stealth mechanism may even be more pronounced for the C.084.09 
KLWESPQEI epitope of MV, poising the HLA-A*02:01 landscape 
(24) and being far more abundant than GILGFVFTL. It would 
be of interest to investigate whether the non-responsiveness of 
CD8+ T cell responses observed against KLWESPQEI during 
convalescence of measles (4) is related to low TCR avidity or 
to activation induced cell death, which could occur after inap-
propriate or prolonged TCR stimulation by high-dose peptide 
(32). Another point to be elucidated is how protective immune 
responses to less abundant peptides can be generated in the 
presence of overwhelming amounts of stealth peptides, as T cells 
compete for interaction with antigen-presenting cells (33), but 
temporal regulation of epitope expression could play a role (24).
The MV peptide set contained, apart from mostly peptides with 
a normal length distribution (8–12 aa), a few low-abundant, non-
canonical 14, 15, and 16-mers. These all failed to be assigned to a 
particular HLA class I allele. In general, peptides longer than 13 
aa in length seem to follow binding motifs less well (Meiring HD, 
unpublished observations). In line with this, the long MV epitope 
sequence H.267.15, categorized as NA in BLCL1112, was also 
detected as a shorter length variant in another BLCL that was 
assigned to an HLA allele (H.267.09, assigned to HLA-B*35:01 
in BLCL1090). Also F.452.14, NA in BLCL1112, was assigned 
as a shorter peptide in the literature [F.452.10, presented by 
HLA*02:01 (22)].
The second major observation was that a substantial part 
(12.3%) of the MV proteome was represented in the overall elu-
cidated HLA class I-presented viral peptidome, with MV-P/V, C, 
M, and H protein sequences being relatively highly sampled by 
HLA class I. Moreover, the majority of epitope regions, except 
in MV-L, had genomic variation with aa substitutions occurring 
at a higher rate than the silent nucleotide substitutions (dN > dS 
sites), potentially representing selective pressure. Of the 18 codons 
with the highest non-synonymous mutation rates (dN ≥ 0.5) in 
the full length viral genome (MV-L codons excluded), 11 were 
within epitope regions, 8 of which were located in MV-P/V/C, 
-M, and -H genes (Table S4 in Supplementary Material). Earlier, 
based on 162 H gene sequences, Saitoh et  al. found evidence 
for significant positive selection pressure on aa H.476 (F- > L), 
adjacent to the HLA-A*02:01-eluted H477.09 (KVSPYLFTVA), 
to be positively selected via an unknown mechanism. In our 
preliminary selection of 58 MV genomes, the H.476 codon had 
a lower dN rate (0.11, dS =  0) than H.481 (Y- >  N), a codon 
within the H477.09 epitope (dN = 0.57; dS = 0.03), implying that 
molecular evolution of this epitope may also be significant when 
tested in more strains, and could well involve T cell mechanisms. 
For another H-derived epitope with high codon variability, 
the HLA-A*02:01-presented octamer H.250.08 (SMYRVFEV, 
Y- >  H, dN =  0.5), CD8+ T cell reactivity has been implied 
in HLA-A2 positive vaccinees and patients using a synthetic 
decamer peptide (SMYRVFEVGV) comprising the naturally 
occurring sequence (22). We observed that epitope abundance 
(≥1,000 cc) rather than the HLA class I locus of HLApMV was 
involved in driving selection of coding mutation in codons. To 
further evaluate the significance of epitope abundance or the 
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role of HLA-A versus-B presentation on codon evolution, more 
insight into the full breadth of human HLA class I-presented 
MV epitope regions is required, as well as a larger set of non-
redundant MV genome sequences, ideally from strains obtained 
directly from acute cases, for codon analysis (2, 3).
With the use of front line mass spectrometry to detect viral 
HLA class I epitopes we have begun to unravel the landscape of 
naturally expressed MV epitopes. Based on our study, it can be 
concluded that MV-specific CD8+ T cells may encounter a widely 
divergent epitope repertoire at the cell surface of an infected 
target cell, including stealth peptides such as the HLA-A*02:01 
presented C.084.09 KLWESPQEI, and also multiple more mod-
estly expressed peptides. Subsequent molecular interactions may 
then be key to either programing for a long-term maintained 
response or the induction of a vigorous short-term response that 
may be immunosuppressive for the host and immunoselective 
for viral variants.
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